These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37737759)

  • 1. SGLT2 Inhibitors and Iron: More Than Meets the Eye.
    Docherty KF
    JACC Heart Fail; 2023 Nov; 11(11):1623-1625. PubMed ID: 37737759
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.
    Imran H; Nester W; Elgendy IY; Saad M
    Ann Med; 2020 Aug; 52(5):178-190. PubMed ID: 32393068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors.
    Mordi IR; Lang CC
    Heart Fail Clin; 2022 Oct; 18(4):529-538. PubMed ID: 36216483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 inhibitors as the bedrock of therapy for heart failure.
    Tuttle KR; Rangaswami J
    Lancet; 2022 Sep; 400(10354):711-713. PubMed ID: 36041473
    [No Abstract]   [Full Text] [Related]  

  • 5. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 Inhibitors in Patients With Heart Failure and Chronic Kidney Disease: Jigsaw Falling Into Place.
    Kristensen SL; Jensen J; Schou M
    J Am Coll Cardiol; 2023 May; 81(19):1915-1917. PubMed ID: 37164524
    [No Abstract]   [Full Text] [Related]  

  • 7. SGLT2 inhibitors in Patients Admitted for Acute Heart Failure: The Earlier the Better.
    Carbone S; Abbate A
    Am J Cardiol; 2024 Mar; 214():177-179. PubMed ID: 38104751
    [No Abstract]   [Full Text] [Related]  

  • 8. SGLT2 inhibitors; suggested mechanism of actions in supporting post-myocardial infarction patients.
    Cotton M; Hawley A
    Future Cardiol; 2023 Jul; 19(9):419-422. PubMed ID: 37702265
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiac Protection.
    Wu VC; Li YR; Wang CY
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure.
    Bjornstad P; Greasley PJ; Wheeler DC; Chertow GM; Langkilde AM; Heerspink HJL; Van Raalte DH
    J Card Fail; 2021 Dec; 27(12):1447-1455. PubMed ID: 34289398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining Iron Supplements With SGLT2 Inhibitor-Stimulated Erythropoiesis in Heart Failure: Should We Be Worried About Thromboembolic Events?
    Packer M; Cleland JGF
    J Card Fail; 2023 Mar; 29(3):403-406. PubMed ID: 36563739
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 Inhibitors Improve Cardiac Failure by Reducing Whole-Body Oxygen Demand: A Hypothesis.
    Onoue T; Kataoka M
    Clin Drug Investig; 2022 Dec; 42(12):1025-1030. PubMed ID: 36344670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Vaduganathan M; Januzzi JL
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding the Role of SGLT2 Inhibitors Beyond Diabetes: A Case-Based Approach.
    Wong E; Nguyen TV
    Sr Care Pharm; 2023 Jun; 38(6):233-238. PubMed ID: 37231576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 Inhibitors in Type 2 Diabetes Mellitus.
    Ferrannini G; Savarese G; Cosentino F
    Heart Fail Clin; 2022 Oct; 18(4):551-559. PubMed ID: 36216485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
    Jhund PS
    Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.
    Perry RJ; Shulman GI
    J Biol Chem; 2020 Oct; 295(42):14379-14390. PubMed ID: 32796035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitors DELIVER benefits in heart failure independently of ejection fraction and diabetes: end of the line or need for new studies?
    Volpe M; Pedicino D
    Eur Heart J; 2022 Nov; 43(44):4614-4615. PubMed ID: 36173867
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.